Jordan Stuart, US equities portfolio manager, Federated Hermes, discusses why after a slump in 2022, biotech stocks especially small caps are attractive options to diversify into for their uncorrelated traits.

Breakfast Bites: 4 at-home tests that reveal how well you’re aging
05:23

Bigger Pic: How smart money is positioning between the Iran oil shock and the AI boom
10:26

Companies To Watch: Is Lululemon losing its shine as growth slows?
10:17